A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Anti-CD38 CAR-T Cells-Sorrento Therapeutics (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Sorrento Therapeutics
  • Most Recent Events

    • 05 Apr 2018 According to the Sorrento Therapeutics media release, IND filing completed and company have started screening patients.
    • 05 Apr 2018 Status changed from not yet recruiting to recruiting, according to the Sorrento Therapeutics media release.
    • 19 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top